Cargando…
Survival after Pure (Acute) Erythroid Leukemia in the United States: A SEER-Based Study
SIMPLE SUMMARY: Pure erythroid leukemia (PEL), a rare subtype of acute myeloid leukemia (AML), is characterized by the proliferation of malignant erythroid precursors. To understand the status of PEL at the population level, a retrospective analysis was conducted using the Surveillance Epidemiology...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417752/ https://www.ncbi.nlm.nih.gov/pubmed/37568757 http://dx.doi.org/10.3390/cancers15153941 |
_version_ | 1785088113763155968 |
---|---|
author | Gera, Kriti Martir, Daniela Xue, Wei Wingard, John R. |
author_facet | Gera, Kriti Martir, Daniela Xue, Wei Wingard, John R. |
author_sort | Gera, Kriti |
collection | PubMed |
description | SIMPLE SUMMARY: Pure erythroid leukemia (PEL), a rare subtype of acute myeloid leukemia (AML), is characterized by the proliferation of malignant erythroid precursors. To understand the status of PEL at the population level, a retrospective analysis was conducted using the Surveillance Epidemiology and End Results (SEER) database from 2000 to 2019. The study included 968 patients with a confirmed diagnosis of PEL, with a median age of 68 years and a higher proportion of males (62%). Among the patients, 62.5% received chemotherapy. The overall survival (OS) rates varied significantly based on age, with better outcomes seen in younger age groups. Chemotherapy was associated with improved OS both in adults and children. However, there were no significant differences in OS based on sex, race, ethnicity, or median household income. Over the two decades of the study, there was no notable improvement in OS, indicating poor outcomes with current chemotherapeutic agents. The study underscores the urgent need for investigational agents that are capable of inducing remission. ABSTRACT: Background: Acute erythroid leukemia (AEL), also known as pure erythroid leukemia, is a rare subtype of acute myeloid leukemia (AML) characterized by the proliferation of malignant erythroid precursors. Outcome data at the population level are scarce. Methods: We performed a retrospective analysis of the Surveillance Epidemiology and End Results (SEER) database. All cases with a histologically confirmed diagnosis of acute (pure) erythroid leukemia during the period of 2000–2019 were included in the study. The Kaplan–Meier method was used to perform survival analysis. The significance of differences between overall survival (OS) was analyzed using the log-rank test. Results: In total, 968 patients were included in the study. The median age was 68 years (range 0–95), 62% of patients were males, and 62.5% (n = 605) were treated with chemotherapy. The median OS for <18, 18–49, 50–64, 65–79 and 80+ age groups was 69, 18, 8, 3 and 1 month, respectively (p < 0.0001). Patients who received chemotherapy had significantly improved OS compared to patients who did not, among both adults (p < 0.0001) and children (p = 0.004). There were no significant differences in OS based on sex, race, ethnicity and median household income. Median OS for adults diagnosed in 2000–2004, 2005–2009, 2010–2014, 2015–2019 was 4, 6, 6 and 3 months, respectively, with no significant differences in OS between these groups. Conclusion: AEL occurs in all age groups but is most common in the elderly. Outcomes are poor with current chemotherapeutic agents, with no improvement in the last two decades. This study stresses the urgent need for investigational agents. |
format | Online Article Text |
id | pubmed-10417752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104177522023-08-12 Survival after Pure (Acute) Erythroid Leukemia in the United States: A SEER-Based Study Gera, Kriti Martir, Daniela Xue, Wei Wingard, John R. Cancers (Basel) Article SIMPLE SUMMARY: Pure erythroid leukemia (PEL), a rare subtype of acute myeloid leukemia (AML), is characterized by the proliferation of malignant erythroid precursors. To understand the status of PEL at the population level, a retrospective analysis was conducted using the Surveillance Epidemiology and End Results (SEER) database from 2000 to 2019. The study included 968 patients with a confirmed diagnosis of PEL, with a median age of 68 years and a higher proportion of males (62%). Among the patients, 62.5% received chemotherapy. The overall survival (OS) rates varied significantly based on age, with better outcomes seen in younger age groups. Chemotherapy was associated with improved OS both in adults and children. However, there were no significant differences in OS based on sex, race, ethnicity, or median household income. Over the two decades of the study, there was no notable improvement in OS, indicating poor outcomes with current chemotherapeutic agents. The study underscores the urgent need for investigational agents that are capable of inducing remission. ABSTRACT: Background: Acute erythroid leukemia (AEL), also known as pure erythroid leukemia, is a rare subtype of acute myeloid leukemia (AML) characterized by the proliferation of malignant erythroid precursors. Outcome data at the population level are scarce. Methods: We performed a retrospective analysis of the Surveillance Epidemiology and End Results (SEER) database. All cases with a histologically confirmed diagnosis of acute (pure) erythroid leukemia during the period of 2000–2019 were included in the study. The Kaplan–Meier method was used to perform survival analysis. The significance of differences between overall survival (OS) was analyzed using the log-rank test. Results: In total, 968 patients were included in the study. The median age was 68 years (range 0–95), 62% of patients were males, and 62.5% (n = 605) were treated with chemotherapy. The median OS for <18, 18–49, 50–64, 65–79 and 80+ age groups was 69, 18, 8, 3 and 1 month, respectively (p < 0.0001). Patients who received chemotherapy had significantly improved OS compared to patients who did not, among both adults (p < 0.0001) and children (p = 0.004). There were no significant differences in OS based on sex, race, ethnicity and median household income. Median OS for adults diagnosed in 2000–2004, 2005–2009, 2010–2014, 2015–2019 was 4, 6, 6 and 3 months, respectively, with no significant differences in OS between these groups. Conclusion: AEL occurs in all age groups but is most common in the elderly. Outcomes are poor with current chemotherapeutic agents, with no improvement in the last two decades. This study stresses the urgent need for investigational agents. MDPI 2023-08-03 /pmc/articles/PMC10417752/ /pubmed/37568757 http://dx.doi.org/10.3390/cancers15153941 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gera, Kriti Martir, Daniela Xue, Wei Wingard, John R. Survival after Pure (Acute) Erythroid Leukemia in the United States: A SEER-Based Study |
title | Survival after Pure (Acute) Erythroid Leukemia in the United States: A SEER-Based Study |
title_full | Survival after Pure (Acute) Erythroid Leukemia in the United States: A SEER-Based Study |
title_fullStr | Survival after Pure (Acute) Erythroid Leukemia in the United States: A SEER-Based Study |
title_full_unstemmed | Survival after Pure (Acute) Erythroid Leukemia in the United States: A SEER-Based Study |
title_short | Survival after Pure (Acute) Erythroid Leukemia in the United States: A SEER-Based Study |
title_sort | survival after pure (acute) erythroid leukemia in the united states: a seer-based study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417752/ https://www.ncbi.nlm.nih.gov/pubmed/37568757 http://dx.doi.org/10.3390/cancers15153941 |
work_keys_str_mv | AT gerakriti survivalafterpureacuteerythroidleukemiaintheunitedstatesaseerbasedstudy AT martirdaniela survivalafterpureacuteerythroidleukemiaintheunitedstatesaseerbasedstudy AT xuewei survivalafterpureacuteerythroidleukemiaintheunitedstatesaseerbasedstudy AT wingardjohnr survivalafterpureacuteerythroidleukemiaintheunitedstatesaseerbasedstudy |